EQL PHARMA AB (7JK) — Financial Flexibility Index

Latest as of December 2025: 0.05x

EQL PHARMA AB (7JK) has a Financial Flexibility Index of 0.05x as of December 2025. Free cash flow of €25.32 Million (operating CF €13.44 Million minus capex €11.87 Million) represents 0% of total liabilities (€543.76 Million). Also explore EQL PHARMA AB annual equity growth to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

0.05x
Free Cash Flow / Total Liabilities

Free Cash Flow

€25.32 Million
Operating CF − Capex

Total Liabilities

€543.76 Million
EUR

Capital Expenditures

€11.87 Million
EUR

EQL PHARMA AB Financial Flexibility Index (2022–2025)

Historical Financial Flexibility Index trend for EQL PHARMA AB across 4 annual periods. See debt-free asset ratio of EQL PHARMA AB to measure how much of total assets are equity-financed.

Annual Financial Flexibility Index for EQL PHARMA AB (2022–2025)

Year-by-year free cash flow to debt coverage for EQL PHARMA AB. For the full company profile including market capitalisation, see EQL PHARMA AB (7JK) total market value.

Year Flexibility Index Free Cash Flow (EUR) Operating CF Total Liabilities YoY Change
2025 0.38x €221.19 Million €-24.65 Million €587.79 Million ▲ +34.6%
2024 0.28x €54.83 Million €-11.44 Million €196.03 Million ▼ -23.9%
2023 0.37x €48.12 Million €27.62 Million €130.94 Million ▼ -34.3%
2022 0.56x €63.92 Million €41.83 Million €114.26 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities